Η XM δεν παρέχει υπηρεσίες σε κατοίκους των Ηνωμένων Πολιτειών Αμερικής.
R
R

RECSilicon


Ειδήσεις

Italy - Factors to watch on July 9

Italy - Factors to watch on July 9 The following factors could affect Italian markets on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . DEBT Treasury to sell up to 8.5 billion euros in bonds at July 11 auction .
A
A
B
E
I
L
P
R
A
I
U

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Liberty Global, Crest Nicholson, NCR Voyix and Baxter International July 5 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2 000 GMT on Friday: * * Private equity firm Carlyle Group is in exclusive talks to acquire Baxter International's BAX.N kidney care spinoff Vantive for more than $4 billion, including debt, a person familiar with the matter told Reuters.
B
B
B
C
G
H
R
S
T
U
B
T

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Thyssenkrupp, Dompe Farmaceutici, Crest Nicholson Updates: BBVA July 5 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Friday: ** Thyssenkrupp TKGA.DE , Salzgitter SZGG.DE and France's Vallourec VLLP.PA are reviewing a sale of their steel joint venture HKM after they were approached by a potential buyer, Germany's largest steelmaker said.
B
B
C
G
H
R
S
T
U
B
T

Italy's Dompe not interested in possible deal with rival drugmaker Recordati

Italy's Dompe not interested in possible deal with rival drugmaker Recordati MILAN, July 5 (Reuters) - Italy's Dompe Farmaceutici is not interested in rival drugmaker Recordati RECI.MI , the biopharmaceutical group's chief executive and chairman said on Friday. "We had looked at it... it is a large company ...we are not on the file," Sergio Dompe told Reuter.
R

Recordati shares rise as investors reportedly circle CVC stake

Recordati shares rise as investors reportedly circle CVC stake MILAN, June 18 (Reuters) - Shares in Italian drugmaker Recordati RECI.MI rose almost 3% on Tuesday, boosted by a report that investment funds KKR KKR.N and TPG TPG.O had expressed preliminary interest in buying a stake in the company. Speculation about the future of Recordati has increased after majority shareholder CVC Capital Partners CVC.AS hired investment banks JP Morgan and Goldman Sachs to explore options for the pharmaceutica
R

Recordati rises after media report on KKR, TPG interest

BUZZ-Recordati rises after media report on KKR, TPG interest ** Shares in Recordati RECI.MI rise as much as 3% after Bloomberg News reported that KKR KKR.N and TPG TPG.O expressed interest in buying a stake in the Italian drugmaker ** The two investment funds, pharma company Angelini Pharma and an Abu Dhabi sovereign fund are among suitors for part or all of the 51.8% stake owned by CVC Capital Partners, Bloomberg News said on Monday, citing people familiar with the matter ** CVC declined to com
R

Italy - Factors to watch on June 18

Italy - Factors to watch on June 18 The following factors could affect Italian markets on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . COMPANIES UNICREDIT CRDI.MI The bank said on Monday it was "well above " MREL requirements set by the Single Resolution Board (SRB) and the Bank of Italy, with MREL eligible liabilities equal to 32.8% of risk-weighe
A
E
I
I
L
L
M
R
U
A
B
B
F
I
U

KKR, TPG express interest in Italian drugmaker Recordati - Bloomberg News

MEDIA-KKR, TPG express interest in Italian drugmaker Recordati - Bloomberg News -- Source link: https://tinyurl.com/28c759fu -- Note: Reuters has not verified this story and does not vouch for its accuracy
R

Eiffage, Quilter, Ricardo

EUROPE RESEARCH ROUNDUP-Eiffage, Quilter, Ricardo June 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Eiffage, Quilter and Ricardo, on Monday. HIGHLIGHTS * Acciona Energia ANE.MC : Morgan Stanley raises to equalweight from underweight * Eiffage FOUG.PA : Goldman Sachs raises to buy from neutral * Quilter Plc QLT.L : JP Morgan raises to overweight from neutral * Ricardo Plc RCDO.L : Berenberg raises to buy from hold * St.
B
C
C
E
H
H
I
I
J
P
P
R
S
V
D
L
N

Carlsberg, Danske Bank, Teleperformance

EUROPE RESEARCH ROUNDUP- Carlsberg, Danske Bank, Teleperformance May 10 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Carlsberg, Danske Bank and Teleperformance, on Friday. HIGHLIGHTS * Carlsberg A/S CARLB.CO : HSBC raises target price to DKK 1040 from DKK 1030 * Danske Bank DANSKE.CO : HSBC cuts target price to DKK 231 from DKK 238 * Hermes HRMS.PA : Jefferies initiates coverage with buy rating; price target EUR 2,650 * Rathbone
3
A
A
A
B
B
B
B
B
C
C
C
C
D
F
G
G
H
I
K
L
M
P
P
R
S
S
S
T
V
W
Z
A
D
S
S

Italy's Recordati CEO: shareholder CVC committed to company long-term growth

BRIEF-Italy's Recordati CEO: shareholder CVC committed to company long-term growth May 9 (Reuters) - Recordati CEO Rob Koremans tells analysts: CVC, AS A SHAREHOLDER, IS VERY COMMITTED TO THE COMPANY'S LONG-TERM GROWTH M&A IS AN IMPORTANT PART OF OUR STRATEGY, VERY HAPPY IF THE NEXT DEAL COULD BE IN RARE DESEASE BUSINESS Further company coverage: R
R

Italy's Recordati confirms guidance after robust Q1 performance

Italy's Recordati confirms guidance after robust Q1 performance May 9 (Reuters) - Italian drug maker Recordati RECI.MI posted a 10.5% rise in its first-quarter core profit on Thursday and confirmed its guidance for 2024 and 2025. The company said it had seen a "robust performance... across all key geographies and products". Interest, taxes, depreciation and amortisation (EBITDA) rose to 244.0 million euros ($262 million) with a margin of 40.2% for the January-March quarter, the Milan-based compa
R

Recordati Q1 EBITDA Up To EUR 244.0 Mln

BRIEF-Recordati Q1 EBITDA Up To EUR 244.0 Mln May 9 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA RECI.MI : Q1 EBITDA EUR 244.0 MILLION VERSUS EUR 220.8 MILLION YEAR AGO CONFIRMS GUIDANCE FOR 2024 AND 2025 Q1 ADJUSTED NET PROFIT EUR 163.7 MILLION VERSUS EUR 155.0 MILLION YEAR AGO Further company coverage: RECI.MI Reporting by Gdansk Ne
R

Italy - Factors to watch on May 9

Italy - Factors to watch on May 9 The following factors could affect Italian markets on Thursday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . DEBT Treasury sells 7.5 billion euros 12-month BOT bills. Subscriptions close at 0900 GMT.
A
B
E
I
I
L
L
P
R
S
S
T
U
A
B
B
B
B
D
F
P
T
I
U

CVC picks banks to explore options for Italy's pharma group Recordati - sources

CVC picks banks to explore options for Italy's pharma group Recordati - sources MILAN, May 8 (Reuters) - CVC Capital Partners has hired JP Morgan and Goldman Sachs to explore options for Italian pharmaceutical group Recordati RECI.MI , two sources close to the matter said on Wednesday. The private equity firm, which owns a majority stake in Recordati, is considering all options, including a sale, a merger with another healthcare company or the creation of a so-called continuation fund, the sourc
G
R

Italy - Factors to watch on May 7

Italy - Factors to watch on May 7 The following factors could affect Italian markets on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . POLITICS Italy's rightwing coalition on Monday passed rules curbing the installation of solar panels on agricultural land , ministers said, in a move that triggered criticism as it could undermine Rome's decarbonisati
F
I
L
L
R
S
U
A
A
B
M
T
I
U

Italy - Factors to watch on April 24

Italy - Factors to watch on April 24 The following factors could affect Italian markets on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . POLITICS Italy's Senate gave final approval on Tuesday to a contested government plan to allow groups who "support motherhood" into abortion clinics to try to deter women from terminating pregnancies.
A
A
E
E
F
M
R
U
A
A
D
I
J
S
T
I
U

CVC explores options for Italy's Recordati, Bloomberg News reports

UPDATE 1-CVC explores options for Italy's Recordati, Bloomberg News reports Adds details and background from paragraph 2 onwards April 23 (Reuters) - CVC Capital Partners is exploring options for its controlling stake in Italian pharmaceutical group Recordati SpA RECI.MI , Bloomberg News reported on Tuesday, citing people familiar with the matter.
R

CVC explores options for Italy's Recordati, Bloomberg News reports

CVC explores options for Italy's Recordati, Bloomberg News reports April 23 (Reuters) - CVC Capital Partners is exploring options for its controlling stake in Italian drugmaker Recordati SpA RECI.MI , Bloomberg News reported on Tuesday, citing people familiar with the matter. Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Shilpi Majumdar
R

Cvc Explores Options For €11 Billion Drugmaker Recordati - Bloomberg News

BRIEF-Cvc Explores Options For €11 Billion Drugmaker Recordati - Bloomberg News April 23 (Reuters) - CVC EXPLORES OPTIONS FOR €11 BILLION DRUGMAKER RECORDATI - BLOOMBERG NEWS Source text for Eikon: https://tinyurl.com/khdn87uv Further company coverage: RECI.MI
R



Όροι

Δημοφιλή περιουσιακά στοιχεία

Δήλωση αποποίησης ευθύνης: Οι οντότητες του ομίλου XM Group παρέχουν υπηρεσίες σε βάση εκτέλεσης μόνο και η πρόσβαση στην ηλεκτρονική πλατφόρμα συναλλαγών μας που επιτρέπει στον ενδιαφερόμενο να δει ή/και να χρησιμοποιήσει το περιεχόμενο που είναι διαθέσιμο στην ιστοσελίδα μας ή μέσω αυτής, δε διαφοροποιεί ούτε επεκτείνει αυτές τις υπηρεσίες πέραν αυτού ούτε προορίζεται για κάτι τέτοιο. Η εν λόγω πρόσβαση και χρήση υπόκεινται σε: (i) Όρους και προϋποθέσεις, (ii) Προειδοποιήσεις κινδύνου και (iii) Πλήρη δήλωση αποποίησης ευθύνης. Ως εκ τούτου, το περιεχόμενο αυτό παρέχεται μόνο ως γενική πληροφόρηση. Λάβετε ιδιαιτέρως υπόψη σας ότι τα περιεχόμενα της ηλεκτρονικής πλατφόρμας συναλλαγών μας δεν αποτελούν παρότρυνση, ούτε προσφορά για να προβείτε σε οποιεσδήποτε συναλλαγές στις χρηματοπιστωτικές αγορές. Η πραγματοποίηση συναλλαγών στις χρηματοπιστωτικές αγορές ενέχει σημαντικό κίνδυνο για το κεφάλαιό σας.

Όλο το υλικό που δημοσιεύεται στην ηλεκτρονική πλατφόρμα συναλλαγών μας προορίζεται για εκπαιδευτικούς/ενημερωτικούς σκοπούς μόνο και δεν περιέχει, ούτε θα πρέπει να θεωρηθεί ότι περιέχει συμβουλές και συστάσεις χρηματοοικονομικές ή σε σχέση με φόρο επενδύσεων και την πραγματοποίηση συναλλαγών, ούτε αρχείο των τιμών διαπραγμάτευσής μας ούτε και προσφορά ή παρότρυνση για συναλλαγή οποιωνδήποτε χρηματοπιστωτικών μέσων ή ανεπιθύμητες προς εσάς προωθητικές ενέργειες.

Οποιοδήποτε περιεχόμενο τρίτων, καθώς και περιεχόμενο που εκπονείται από την ΧΜ, όπως απόψεις, ειδήσεις, έρευνα, αναλύσεις, τιμές, άλλες πληροφορίες ή σύνδεσμοι προς ιστότοπους τρίτων το οποίο περιέχεται σε αυτήν την ιστοσελίδα παρέχεται «ως έχει», ως γενικός σχολιασμός της αγοράς και δεν αποτελεί επενδυτική συμβουλή. Στον βαθμό που οποιοδήποτε περιεχόμενο ερμηνεύεται ως επενδυτική έρευνα, πρέπει να λάβετε υπόψη και να αποδεχτείτε ότι το περιεχόμενο δεν προοριζόταν και δεν έχει προετοιμαστεί σύμφωνα με τις νομικές απαιτήσεις που αποσκοπούν στην προώθηση της ανεξαρτησίας της επενδυτικής έρευνας και ως εκ τούτου, θα πρέπει να θεωρηθεί ως επικοινωνία μάρκετινγκ σύμφωνα με τους σχετικούς νόμους και κανονισμούς. Παρακαλούμε εξασφαλίστε ότι έχετε διαβάσει και κατανοήσει τη Γνωστοποίησή μας περί Μη ανεξάρτητης επενδυτικής έρευνας και την Προειδοποίηση ρίσκου όσον αφορά τις παραπάνω πληροφορίες, τις οποίες μπορείτε να βρείτε εδώ.

Προειδοποίηση ρίσκου: Τα κεφάλαιά σας κινδυνεύουν. Τα προϊόντα με μόχλευση ενδέχεται να μην είναι κατάλληλα για όλους. Παρακαλούμε λάβετε υπόψη σας τη Γνωστοποίηση ρίσκου.